Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Overview
- Phase
- Phase 3
- Intervention
- TP-03
- Conditions
- Blepharitis
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Enrollment
- 412
- Locations
- 21
- Primary Endpoint
- The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid.
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.
Detailed Description
This Phase 3 study is a randomized, controlled, multicenter, double-masked, parallel trial to compare the safety and efficacy of TP-03 to vehicle control for the treatment of Demodex blepharitis. The primary objective of the study is to assess the safety and efficacy of TP-03, 0.25% compared to its vehicle from Day 1 to Day 43 in adult participants with mild to severe Demodex blepharitis. The primary efficacy endpoint will be cure based upon collarettes. Safety will be determined by assessing adverse effects related to the treatment as well as evaluating any changes in visual acuity, intraocular pressure, slit lamp biomicroscopy, endothelial cell density, hematology, blood chemistry, and urinalysis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
- •Meet all of the following criteria in at least one eye: Have more than 10 lashes with collarettes present on the upper lid; have at least mild erythema of the upper eyelid margin; have an average Demodex density, upper and lower eyelids combined, of 1.5 or more mites per lash
Exclusion Criteria
- •Have used lid hygiene products within 14 days of Screening or unwilling to forego the use of lid hygiene products during the study
- •Have used a prostaglandin analogue to promote eyelash growth within 30 days of Screening or any plans to initiate treatment during the study
- •Have used artificial eyelashes or eyelash extensions within 7 days of Screening or be unwilling to forego their use during the study
- •Be pregnant or lactating at the time of Screening
Arms & Interventions
Active
TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
Intervention: TP-03
Control
Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
Intervention: TP-03 Vehicle
Outcomes
Primary Outcomes
The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid.
Time Frame: 43 days
The proportion of subjects cured where cure is defined as 0-2 lashes with collarettes on the upper eyelid of the analysis eye. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values
Secondary Outcomes
- The Proportion of Participants With Their Demodex Mites Eradicated.(43 days)
- The Proportion of Participants Cured Based on Erythema Score.(43 days)
- The Proportion of Participants Cured Based on a Composite of Collarette Score and Erythema Score(43 days)